Research and Clinical Trials
Laboratory and Translational Research in the John C. Davis Program
Translational studies are a fundamental aspect of the modern treatment of plasma cell diseases. A major focus of our research is identifying the genes and proteins that enable malignant plasma cells to cause disease and to survive despite modern treatments. The Screening to Improve Survival in AL Amyloidosis trial for patients with lambda smoldering myeloma or monoclonal gammopathy of undetermined significance helps patients to be diagnosed before they are sick by identifying the light-chain genes in their plasma cells.
Our research staff handles the bone marrow, blood and stem cells of patients willing to donate to advance our knowledge these diseases. For minimal residual disease testing we employ a state-of-the-art genetic test that is performed on bone marrow cells from diagnosis and at the time of achieving a complete response.
These clinical trials are currently open and recruiting patients at Tufts MC:
Screening to Improve Survival in AL Amyloidosis
For systemic AL amyloidosis
A Study to evaluate the Effectiveness and Safety of CAEL-101 in Patients with Mayo Stage IIIa AL Amyloidosis
A Study to evaluate the Effectiveness and Safety of CAEL-101 in Patients with Mayo Stage IIIb AL Amyloidosis
A Phase 4 Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of Hereditary Transthyretin-Mediated (ATTRv) Amyloidosis With a V122I or T60A Mutation
For smoldering multiple myeloma
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma